Currently, we have four dedicated R&D centres in operation, one each for Bristol-Myers Squibb (BMS), Baxter Inc., Amgen Inc., and Herbalife. The centres are equipped with infrastructure that conforms to industry regulations as well as the client’s internal requirements. At each centre, a dedicated multidisciplinary scientific team works with the client on a full-time engagement basis, to accelerate their R&D.
Commenced in 2007
Contract till 2026
Largest R&D centre in Asia for BMS
Focus on novel research in small and large molecules
About 500 scientists engaged at the facility
Produced nine drug candidates for further study & advanced new compounds for first-inhuman studies
Commenced in 2013
Contract till 2024
Focus on product and analytical development, pre-clinical evaluation in parenteral nutrition and renal therapy
Commenced in 2016
Exclusive R&D centre for Amgen Inc. in India
Focus on medicinal and process chemistry, biologics, bioprocess, drug metabolism, pharmacokinetics, bioanalytical research and pharmaceutical development
185 scientists engaged at the facility
Commenced in 2016
Herbalife’s first nutrition R&D lab in India
cGMP lab enclosed within the facility
Focus on product development, sensory evaluation and testing, scientific content writing, project management, formulation development, analytical service, stability study and other related services
During the year, the dedicated R&D centre business unit gained considerable traction due to multiple reasons. First, we expanded and extended our agreement with Baxter Healthcare Corporation. Second, the extension of collaborations with BMS and Amgen achieved in FY18 brought in additional revenues.
The collaboration for Baxter Global Research Centre (BGRC) has been renewed up to 2024. As per the renewed contract, a new laboratory infrastructure was commissioned for Baxter.
These strong collaborations and their successful renewals manifest the clients’ growing confidence in our scientific expertise across the drug delivery continuum.
We also commissioned a new facility for BMS in accordance with the agreement signed in FY18. This facility is spread over 25,000 sq. ft. comprising laboratory and office facilities and houses an additional team of about 75 Syngene scientists.
Syngene successfully completed the development and clinical supplies manufacturing of drug product for Amgen, which has been filed as an Investigational New Drug (IND) application with USFDA, by Amgen Inc.
Partnership of Continued Trust
The Baxter Global Research Centre, set up by Syngene in 2013, is today an important part of Baxter’s overall global R&D support system. This state-of-the-art facility focusses on product and analytical development, pre-clinical evaluation in parenteral nutrition and renal therapy. It also supports Baxter in R&D of medical products and devices catering to patients both in India and around the world. In FY19, Baxter expanded the agreement both in scope and duration, extending the contract to 2024. The successful renewal of this major collaboration with a global healthcare company bears testimony to the deep trust and confidence Syngene has secured for its discovery and development expertise, therapeutic knowledge and cuttingedge processes. A new laboratory was commissioned during the year, in line with the new agreement, to strengthen the existing capacity of BGRC to work on more complex projects. Starting with around 150 Syngene scientists working at the centre, the team strength has grown over the years, aligned with Baxter’s project requirements.
Partnership of Continued Scientific Intelligence
Syngene has a long-standing partnership with Bristol-Myers Squibb (BMS) spanning two decades. The engagement started with small projects and gradually expanded to cover broader scientific domains across discovery and development. In 2007, Syngene set up its first dedicated R&D Centre with the commissioning of the Biocon Bristol-Myers Squibb Research & Development Centre (BBRC). This is the largest research facility for BMS outside the US and an integral part of their global R&D network. Extensive scientific research is carried out at BBRC in pursuit of developing new and better drugs. Scientific projects tend to be long-term projects requiring consistent effort. By renewing the agreement up to 2026 in FY18, BMS and Syngene have demonstrated their commitment towards all the ongoing projects and those in the pipeline. It is also an affirmation of the high level of scientific work undertaken by Syngene’s scientists.